Skip to main content
. 2021 Jun 2;18(3):157–163. doi: 10.1016/j.reumae.2020.10.002

Table 5.

Relationship between level of satisfaction (patient and doctor) very favourable (≥8) or not (<8) and demographic and clinical variables.

Variable Level of patient satisfaction
Level of doctor satisfaction
<8 ≥8 <8 ≥8
% % P % % P
Sex M 70.1 69.9 .972 79.5 68.2 .054
V 29.9 30.1 20.5 31.8
ICTs skills No 67.0 43.6 <.001 72.6 44.0 <.001
Yes 33.0 56.4 27.4 56.0
Level of education Primary 73.2 47.2 <.001 68.5 49.6 .002
Secondary 20.6 34.1 27.4 32.1
Higher 6.2 18.7 4.1 18.3
Disability No 77.3 84.8 .078 75.3 84.7 .048
Yes 22.7 15.2 24.7 15.3
Goes in own car No 24.7 25.5 .883 24.7 25.4 .887
Yes 75.3 74.5 75.3 74.6
Goes in public transport No 75.3 74.5 .883 75.3 74.6 .887
Yes 24.7 25.5 24.7 25.4
Goes alone No 37.1 36.6 .924 37.0 36.6 .955
Yes 62.9 63.4 63.0 63.4
Needs accompaniment No 75.3 81.3 .185 74.0 81.2 .158
Yes 24.7 18.7 26.0 18.8
Difficult diagnosis No 36.1 37.7 .774 34.2 37.9 .552
Yes 63.9 62.3 65.8 62.1
Psychiatric comorbidites No 89.7 92.4 .384 89.0 92.4 .340
Yes 10.3 7.6 11.0 7.6
RTC with provision of analyses/tests No 36.1 37.4 .811 47.9 35.1 .037
Yes 63.9 62.6 52.1 64.9
RTC with provision of analyses/tests  + adjustment to treatment No 35.1 32.2 .601 45.2 30.5 .014
Yes 64.9 67.8 54.8 69.5
Cardiovascular comorbidity No 37.1 49.3 .032 37.0 48.6 .068
Yes 62.9 50.7 63.0 51.4
Treatment with MTX/anti-TNF/GC No 70.1 60.7 .089 71.2 61.1 .099
Yes 29.9 39.3 28.8 38.9
Treatment with biophosphonates/Ca No 63.9 69.9 .257 69.9 68.4 .811
Yes 36.1 30.1 30.1 31.6
Treatment with MTX/anti-TNF/GC No 75.3 70.5 .352 79.5 70.0 .100
Yes 24.7 29.5 20.5 30.0
Rural/urban residence Rural 45.4 39.0 .258 42.5 39.9 .687
Urban 54.6 61.0 57.5 60.1
Distance travelled for face-to-face consultation <25 km 52.6 62.9 .095 58.9 61.1 .848
25−50 km 29.9 20.1 24.7 21.6
>50 km 17.5 17.1 16.4 17.3
Grouped diagnoses AR/APS 34.02 27.03 .468 31.08 27.99 .485
OP/STR osteoarthritis 36.08 37.84 35.14 37.91
Fibromyalgia 4.12 5.68 5.41 5.34
RPM 1.03 3.78 0 3.82

Ca: Calcium; GC: Glucocorticoids; ICTs: Information and Communication Technologies; M: Men; MTX: Methotrexate; OP: Osteoporosis; PsA: Psoriatic Arthritis; RA: Rheumatoid Arthritis; RPM: Rheumatic Polymyalgia; RTC: Rheumatology Teleconference; STR: Soft Tissue Rheumatism; TNF: Tumour Necrosis Factor W: Women;